Shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) saw an uptick in trading volume on Friday . 157,593 shares traded hands during trading, a decline of 7% from the previous session’s volume of 169,820 shares.The stock last traded at $6.93 and had previously closed at $6.97.

Several research firms have issued reports on AQXP. Leerink Swann lowered their price target on shares of Aquinox Pharmaceuticals from $26.00 to $21.00 and set an “outperform” rating for the company in a report on Wednesday, March 16th. Needham & Company LLC started coverage on shares of Aquinox Pharmaceuticals in a research report on Thursday, May 12th. They set a “buy” rating and a $25.00 price objective for the company. Finally, Jefferies Group reaffirmed a “hold” rating and set a $9.00 price objective (down previously from $19.00) on shares of Aquinox Pharmaceuticals in a research report on Tuesday, March 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Aquinox Pharmaceuticals has an average rating of “Buy” and an average price target of $19.86.

The firm’s market capitalization is $121.34 million. The stock’s 50 day moving average is $7.18 and its 200-day moving average is $8.94.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its earnings results on Tuesday, May 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.04. On average, analysts forecast that Aquinox Pharmaceuticals Inc. will post ($1.79) earnings per share for the current year.

An institutional investor recently bought a new position in Aquinox Pharmaceuticals stock. Numeric Investors LLC bought a new stake in Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 185,810 shares of the company’s stock, valued at approximately $2,319,000. Numeric Investors LLC owned approximately 1.08% of Aquinox Pharmaceuticals as of its most recent SEC filing.

Aquinox Pharmaceuticals, Inc, formerly Aquinox Pharmaceuticals (USA) Inc, is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals (Canada) Inc is a wholly owned subsidiary of the Company.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.